Efficacy and Safety of Angiotensin II Type 1 Receptor Blocker/Calcium Channel Blocker Combination Therapy for Hypertension: Focus on a Single-Pill Fixed-Dose Combination of Valsartan and Amlodipine
Free accessResearch articleFirst published online February, 2012
Efficacy and Safety of Angiotensin II Type 1 Receptor Blocker/Calcium Channel Blocker Combination Therapy for Hypertension: Focus on a Single-Pill Fixed-Dose Combination of Valsartan and Amlodipine
Adequate lowering of blood pressure reduces the risk of hypertension-induced cardiovascular events. Worldwide, blood pressure is not optimally controlled and more effective management is needed. The efficacy and tolerability of angiotensin II type 1 receptor blockers (ARBs) have led to their widespread use. Calcium channel blockers (CCBs) are highly effective antihypertensives and amlodipine has a long half-life in the circulation. The combination of an ARB with a CCB as a single-pill, fixed-dose treatment is emerging as possibly the best therapy for preventing cardiovascular disease. Although many kinds of ARB are used in such combinations, amlodipine is mainly used as the CCB. Thus, differences in safety and efficacy among single-pill ARB/CCBs depend mainly on the ARB. Not all ARBs have the same effects and some of these may be molecular (or differential) rather than class (or common) effects. This review discusses the safety and efficacy of ARB/CCB combination therapy, with particular focus on a single-pill, fixed-dose combination of valsartan/amlodipine.
ChobanianAVBakrisGLBlackHR: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension2003; 42: 1206–1252.
2.
OgiharaTKikuchiKMatsuokaH: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res2009; 32: 3–107.
3.
YoshimuraMKawaiM: Synergistic inhibitory effect of angiotensin II receptor blocker and thiazide diuretic on the tissue renin-angiotensin—aldosterone system. J Renin Angiotensin Aldosterone Syst2010; 11: 124–126.
4.
MiuraSKarnikSSSakuK: Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst2011; 12: 1–7.
5.
RedonJFabiaMJ: Efficacy in angiotensin receptor blockade: A comparative review of data with olmesartan. J Renin Angiotensin Aldosterone Syst2009; 10: 147–156.
6.
ZhengZShiHJiaJ: A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst2011; 12: 365–374.
7.
MiuraSSakuK: Do angiotensin II type 1 receptor blockers have molecular effects?Hypertens Res2010; 33: 105–106.
8.
ManciaGDe BackerGDominiczakA: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens2007; 25: 1105–1187.
9.
PiccaMAgozzinoFPelosiG: Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther2004; 21: 76–86.
10.
TsutamotoTNishiyamaKYamajiM: Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. Hypertens Res2010; 33: 118–122.
11.
NarumiHTakanoHShindoS: Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertens Res2011; 34: 62–69.
12.
MiuraSFujinoMSakuK: Angiotensin II receptor blocker as an inverse agonist: A current perspective. Curr Hypertens Rev2005; 1: 115–121.
13.
MiuraSFujinoMHanzawaH: Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem2006; 281: 19288–19295.
14.
MiuraSKiyaYKanazawaT: Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol2008; 22: 139–146.
15.
YasudaNMiuraSAkazawaH: Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep2008; 9: 179–186.
16.
FujinoMMiuraSKiyaY: A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects. Hypertens Res2010; 33: 1044–1052.
17.
CalvoCHermidaRCAyalaDE: Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens2004; 22: 837–846.
18.
PadiaSHHowellNLSiragyHM: Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension2006; 47: 537–544.
19.
WangLLiGHChenH: Effect of vasartan-eluting stents on the expression of angiotensin II type 2 receptor. Chin Med J2006; 119: 601–604.
20.
HariaMWagstaffAJ: Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs1995; 50: 560–586.
21.
FaulknerJKMcGibneyDChasseaudLF: The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol1986; 22: 21–25.
22.
AbuissaHJonesPGMarsoSP: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. J Am Coll Cardiol2005; 46: 821–826.
23.
PhilippTSmithTRGlazerR: Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther2007; 29: 563–580.
24.
NathanSPepineCJBakrisGL: Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension2005; 46: 637–642.
25.
BlackHRBaileyJZappeD: Valsartan: more than a decade of experience. Drugs2009; 69: 2393–2414.
26.
CohnJNTognoniG, Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med2001; 345: 1667–1675.
27.
PfefferMAMcMurrayJJVelazquezEJ: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med2003; 349: 1893–1906.
28.
JuliusSKjeldsenSEWeberM: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004; 363: 2022–2031.
29.
MochizukiSDahlöfBShimizuM: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity—mortality study. Lancet2007; 369: 1431–1439.
30.
SawadaTYamadaHDahlöfB: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: Kyoto Heart Study. Eur Heart J2009; 30: 2461–2469.
31.
StergiouGSMakrisTPapavasiliouM: Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens2005; 23: 883–889.
32.
PoldermansDGlazesRKargiannisS: Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther2007; 29: 279–289.
33.
AllemannYFraileBLambertM: Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich)2008; 10: 185–194.
34.
SchraderJSalvettiACalvoC: The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract2009; 63: 217–225.
35.
DestroMLuckowASamsonM: Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: A randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens2008; 2: 294–302.
36.
FlackJMCalhounDASatlinL: Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens2009; 23: 479–489.
37.
SmithTRPhilippTVaisseB: Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich)2007; 9: 355–364.
38.
BrachmannJAnsariAMahlaG: Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther2008; 25: 399–411.
39.
MaleskerMAHillemanDE: Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy. Manag Care2010; 19: 36–42.
